AA
STOK icon

ALPS Advisors’s Stoke Therapeutics STOK Stock Holding History

ALPS Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Buy
63,010
+16,512
+36% +$530K 0.01% 511
2026
Q1 		$1.51M Sell
46,498
-20,004
-30% -$656K 0.01% 458
2025
Q4 		$2.11M Buy
66,502
+21,838
+49% +$656K 0.01% 384
2025
Q3 		$1.05M Buy
44,664
+15,234
+52% +$261K 0.01% 503
2025
Q2 		$334K Sell
29,430
-10,460
-26% -$99.3K ﹤0.01% 897
2025
Q1 		$265K Sell
39,890
-2,940
-7% -$27.4K ﹤0.01% 933
2024
Q4 		$472K Buy
+42,830
New +$526K ﹤0.01% 621
2023
Q4 		– Sell
-32,647
Closed -$129K – 1011
2023
Q3 		$129K Buy
32,647
+165
+0.5% +$1.08K ﹤0.01% 966
2023
Q2 		$345K Buy
32,482
+3,397
+12% +$36.1K ﹤0.01% 741
2023
Q1 		$242K Buy
29,085
+2,336
+9% +$21.1K ﹤0.01% 964
2022
Q4 		$247K Buy
26,749
+5,234
+24% +$54.4K ﹤0.01% 968
2022
Q3 		$276K Sell
21,515
-1,730
-7% -$27.6K ﹤0.01% 930
2022
Q2 		$307K Sell
23,245
-15,148
-39% -$230K ﹤0.01% 786
2022
Q1 		$808K Sell
38,393
-4,178
-10% -$83.7K 0.01% 332
2021
Q4 		$1.02M Sell
42,571
-2,463
-5% -$58.8K 0.01% 354
2021
Q3 		$1.15M Sell
45,034
-3,317
-7% -$92.5K 0.01% 376
2021
Q2 		$1.63M Buy
+48,351
New +$1.71M 0.01% 353

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ALPS Advisors's STOK Position: Q2 2026 in Review

ALPS Advisors increased its Stoke Therapeutics (STOK) stake by 36% in Q2 2026, buying an estimated $530K and bringing the position to 63,010 shares worth $2.06M. The position accounts for 0.01% of the portfolio, ranked #511.

ALPS Advisors first reported a position in STOK in Q2 2021 and has held it in 17 quarters since. The position peaked at $2.11M in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • ALPS Advisors held 63,010 shares of Stoke Therapeutics worth $2.06M as of Q2 2026.
  • ALPS Advisors bought 16,512 Stoke Therapeutics shares in Q2 2026, an estimated $530K.
  • Stoke Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #511 holding.
  • ALPS Advisors first reported a position in Stoke Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • ALPS Advisors's Stoke Therapeutics position peaked at $2.11M in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.